In Elderly Persons Live Attenuated Influenza A Virus Vaccines Do Not Offer an Advantage over Inactivated Virus Vaccine in Inducing Serum or Secretory Antibodies or Local Immunologic Memory
Overview
Affiliations
In a double-blind, randomized trial, 102 healthy elderly subjects were inoculated with one of four preparations: (i) intranasal bivalent live attenuated influenza vaccine containing cold-adapted A/Kawasaki/86 (H1N1) and cold-adapted A/Bethesda/85 (H3N2) viruses; (ii) parenteral trivalent inactivated subvirion vaccine containing A/Taiwan/86 (H1N1), A/Leningrad/86 (H3N2), and B/Ann Arbor/86 antigens; (iii) both vaccines; or (iv) placebo. To determine whether local or systemic immunization augmented mucosal immunologic memory, all volunteers were challenged intranasally 12 weeks later with the inactivated virus vaccine. We used a hemagglutination inhibition assay to measure antibodies in sera and a kinetic enzyme-linked immunosorbent assay to measure immunoglobulin G (IgG) and IgA antibodies in sera and nasal washes, respectively. In comparison with the live virus vaccine, the inactivated virus vaccine elicited higher and more frequent rises of serum antibodies, while nasal wash antibody responses were similar. The vaccine combination induced serum and local antibodies slightly more often than the inactivated vaccine alone did. Coadministration of live influenza A virus vaccine did not alter the serum antibody response to the influenza B virus component of the inactivated vaccine. The anamnestic nasal antibody response elicited by intranasal inactivated virus challenge did not differ in the live, inactivated, or combined vaccine groups from that observed in the placebo group not previously immunized. These results suggest that in elderly persons cold-adapted influenza A virus vaccines offer little advantage over inactivated virus vaccines in terms of inducing serum or secretory antibody or local immunological memory. Studies are needed to determine whether both vaccines in combination are more efficacious than inactivated vaccine alone in people in this age group.
Influenza vaccine for chronic obstructive pulmonary disease (COPD).
Kopsaftis Z, Wood-Baker R, Poole P Cochrane Database Syst Rev. 2018; 6:CD002733.
PMID: 29943802 PMC: 6513384. DOI: 10.1002/14651858.CD002733.pub3.
Vaccines for preventing influenza in the elderly.
Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas R Cochrane Database Syst Rev. 2018; 2:CD004876.
PMID: 29388197 PMC: 6491101. DOI: 10.1002/14651858.CD004876.pub4.
Influenza vaccination in the elderly.
Smetana J, Chlibek R, Shaw J, Splino M, Prymula R Hum Vaccin Immunother. 2017; 14(3):540-549.
PMID: 28708957 PMC: 5861798. DOI: 10.1080/21645515.2017.1343226.
Falkeborn T, Hinkula J, Olliver M, Lindberg A, Maltais A Virol J. 2017; 14(1):44.
PMID: 28253901 PMC: 5335733. DOI: 10.1186/s12985-017-0698-4.
Development and applications of single-cycle infectious influenza A virus (sciIAV).
Nogales A, Baker S, Domm W, Martinez-Sobrido L Virus Res. 2015; 216:26-40.
PMID: 26220478 PMC: 4728073. DOI: 10.1016/j.virusres.2015.07.013.